We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands ...

bluebird bio (BLUE) had made great progress in advancing its gene therapy lovo-cel for the treatment of patients with sickle cell disease [SCD]. That's because the FDA had accepted its Biologics ...

bluebird bio BLUE is a clinical-stage biotech company focused on developing gene therapies for severe genetic diseases. The company has developed a robust pipeline using its lentiviral gene addition ...

Editor's note: This story was updated at 210p ET with details on price, availability, and "black box" warning. The U.S. FDA Friday approved bluebird bio's (NASDAQ:BLUE) Lyfgenia (lovo-cel), a gene ...

Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement. Under the ...

Fintel reports that on December 8, 2023, Morgan Stanley upgraded their outlook for Bluebird bio (NASDAQ:BLUE) from Underweight to Equal-Weight. As of November 27, 2023, the average one-year price ...

Sept 24 (Reuters) - Bluebird bio (BLUE.O), opens new tab will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a second major restructuring in two years ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene ...

March 28 (Reuters) - Gene therapy maker bluebird bio (BLUE.O), opens new tab said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at ...